# A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

Source: https://onco.cc/trials/nct06549595/  
OnCo record `nct06549595` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of AZD0486 in follicular lymphoma, run by AstraZeneca, now recruiting.

## Summary

A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients is a phase 3 interventional study registered as NCT06549595 by AstraZeneca, with 1018 participants planned, started 2024-08-07 and due to reach its primary completion in 2031-11-26. Interventions recorded: Surovatamig, R-CHOP, R-CVP, BR. Conditions listed: Untreated Follicular Lymphoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06549595
- Phase: 3
- Setting: A Phase III, Multicentre, Randomised, Open-label Study to Compare the Efficacy and Safety of AZD0486 Plus Rituximab Versus Chemotherapy Plus Rituximab in Previously Untreated Participants With Follicular Lymphoma (SOUNDTRACK-F1)
- Sponsor: AstraZeneca
- Enrolled: 1018

## Sources

- ClinicalTrials.gov NCT06549595: https://clinicaltrials.gov/study/NCT06549595

## Connected records

- cancers: [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/)
- drugs: [AZD0486](https://onco.cc/drugs/azd0486/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct06549595.json